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A B S T R A C T
Objectives: Cell injury releases actin, the most abundant cell protein. Gelsolin and vitamin D binding
protein (VDBP) together depolymerise and clear cell-free actin. Impaired actin clearance is associated
with several diseases and correlates with clinical outcome. The actin scavenging system was
investigated in pre-eclampsia (PE), a procoagulant and proinﬂammatory state with placental and
vascular damage.
Study design: Plasma gelsolin and actin free VDBP (AFVDBP) were measured in PE (early onset
<33 weeks; late onset 36 weeks), matched normal pregnant (normP) and non-pregnant (nonPr)
women, using commercially available ELISAs. Longitudinal samples from normP and women who
subsequently developed PE were also analysed.
Results: Plasma gelsolin fell during pregnancy (p = 0.0002), with a concomitant rise in actin-free VDBP
(p < 0.001). Gelsolin concentrations were only signiﬁcantly lower in established PE (p < 0.05) when
compared to non-pregnant controls.
Conclusions: We have shown that the components of the actin clearance system, gelsolin and AFVDBP,
are altered in normal pregnancy and further changes occur in established PE, suggesting depleted actin
clearance in PE. Whether this is a cause or consequence of PE pathophysiology requires further
investigation.
 2013 The Authors. Published by Elsevier Ireland Ltd. 
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Pre-eclampsia (PE) affects 3–5% of pregnancies, causing
maternal and perinatal mortality or morbidity [1] and lasting
health implications for both mother and baby [2]. It is char-
acterised by a maternal systemic inﬂammatory response, endo-
thelial cell dysfunction and increased coagulation, secondary to
disordered placental function [1]. In PE, the physiological
activation of coagulation, present in normal pregnancy, is
exaggerated with excessive platelet activation and intervillous
ﬁbrin deposition in the placenta [3,4]. As the causative factor(s)
originate from the placenta, removal of the placenta remains the
only effective treatment.
Many placental derived factors are implicated in the maternal
syndrome [5], with anti-angiogenic factors being the best
characterised. Alternatives include ‘danger’ molecules released
from damaged or dying cells that become toxic in the extracellular* Corresponding author. Tel.: +44 1865 221016; fax: +44 1865 769141.
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Open access under CC Bmilieu, such as actin [6,7]. Extracellular actin can damage
microvascular capillaries, activate platelets and impede clot lysis,
all effects associated with the excessive procoagulation evident in
PE [4,8,9]. An efﬁcient system comprising gelsolin [10,11] and
vitamin D binding protein (VDBP) works to cleave extracellular
actin and inhibit repolymerisation, blocking its thrombotic effects
[9,12,13]. Meanwhile, hypogelsolinemia is common in trauma and
inﬂammatory diseases, with higher gelsolin levels correlating with
improved mortality rates [14,15]. Restoring circulating gelsolin
and VDBP levels may therefore avoid more serious complications
and reduce mortality rates [16]. Gelsolin is also an attractive
candidate for therapy as it modulates several proinﬂammatory
pathways [14].
Cell-free actin levels are increased in normal pregnancy,
shown by increased actin-VDBP complex levels [17]. In PE there
is potential for a further increase in circulating actin due to
increased placental apoptosis and necrosis and activated
endothelial and immune cells [18,19]. It is not known how
the components of the actin scavenging system change
during normal pregnancy or PE. Therefore, the aim of this pilot
study was to determine the circulating levels of gelsolin and
actin-free VDBP (AFVDBP; to measure the actin binding capacity
of VDBP) in normal pregnancy and PE, compared to non-
pregnant women.Y-NC-ND license.
Table 1
Clinical characteristics of participants recruited to a cross-sectional study investigating changes in plasma gelsolin and actin free vitamin D binding protein levels in normal
pregnancy and pre-eclampsia (PE). A single plasma sample was collected from women diagnosed with either early onset (<33 weeks; n = 10) or late onset (36 weeks; n = 10)
PE and matched non pregnant (NonPr; n = 10/group) and normal pregnant (NormP; n = 10/group) women. Data are shown as median (range).











Early onset PE matched group
NonP (n = 10) 32 (21–38) N/A N/A 8/10 N/A N/A N/A
NormP (n = 10) 33 (23–37) 30+4 (24+2–33+4) 40+5 (39+5–42+0) 8/10 125/80 (120–140) (60–86) None detected 3613.5 (3069–4002)
PE (n = 10) 30 (21–38) 29+2 (24+4–32+5) 31+2*** (25+4–33+3) 8/10 187.5/120*** (170–215)
(110–130)
3803.5 (940–9433) 1245.5*** (490–2009)
Late onset PE matched group
NonP (n = 10) 31.5 (23–36) N/A N/A 6/10 N/A N/A N/A
NormP (n = 10) 33 (20–36) 37+1 (35+3–38+3) 39+5 (38+5–40+4) 6/10 130/79 (110–137) (70–88) None detected 3480.5 (3022–3842)
PE (n = 10) 31 (21–39) 37+3 (35+5–38+6) 38+0*** (36+1–38+6) 6/10 166/110*** (148–1
90) (100–120)
1022 (727–1687) 2911.5** (2241–3592)
NonPr, non-pregnant recruits; NormP, normal pregnancy and PE, pre-eclampsia.
** p < 0.01 compared to matched normP.
*** p < 0.002 compared to matched normP.
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To determine whether PE was associated with changes in
circulating levels of plasma AFVDBP and gelsolin, a single blood
sample was taken from women with PE (early onset (<33 weeks
gestation; n = 10) and late onset PE (36 weeks gestation; n = 10))
and matched to normal pregnant women (age (4 years), parity (0,
1–3, 4+), and gestational age (13 days)) (normP) and non-pregnant
(age and parity) (nonPr) controls (Table 1).
Longitudinal samples were collected to determine changes in
plasma AFVDBP and gelsolin over the course of normal
pregnancy (normP), prior to and subsequent to the onset of
PE. These samples were collected from pregnant women
recruited to the Oxford Pregnancy Biobank (n = 10) in the ﬁrst
(11–13 weeks gestation), second (20–22 weeks) and third (30–
34 weeks) trimesters of pregnancy (Table 2). Blood samples from
matched (age and parity) nonPr controls were also collected
(n = 10). In those women who subsequently developed PE, 4
developed early onset PE (<33 weeks) and 11 late onset PE
(35 weeks gestation).
All pre-eclamptic women were recruited in the hospital
following a positive diagnosis. Matched normal pregnant and
non-pregnant women were recruited during routine prenatal
appointments and from the community. All blood samples were
collected into EDTA tubes, plasma isolated and the samples stored
at 80 8C until analysis. Due to the potential for cell stress and
therefore release of actin, no samples were collected during labour.
Normal pregnant women had a healthy singleton pregnancy and
no history of chronic illness. Pre-eclampsia was deﬁned as new
hypertension (diastolic blood pressure 90 mm Hg on two
consecutive occasions) and new proteinuria (24 h secretion ofTable 2
Clinical characteristics of matched non pregnant (NonPr), normal pregnant (NormP) and
changes in plasma gelsolin and actin free vitamin D binding protein levels during norma
samples were collected from each gestation and once PE had developed. Data are show





NonP (n = 10) 29 (20–33) N/A 9/10 N/A
NormP (n = 10) 29 (19–34) 40+1 (37–41+5) 9/10 122
PE (n = 10) 29.5 (18–35) 37+2*** (22+3–40+0) 9/10 160
NonPr, non-pregnant recruits; NormP, normal pregnancy and PE, pre-eclampsia.
* p < 0.05 compared to matched normP.
*** p < 0.002 compared to matched normP.500 mg). The Oxfordshire Research Ethics Committee C approved
this study (ref. 09/H0606/10) and informed written consent was
obtained from all recruits.
Gelsolin and AFVDBP concentrations were determined using
commercially available ELISA kits (Gelsolin: USCN Life Sciences
Inc.; VitDBP: Immundiagnostik AG) according to the manufac-
turers’ instructions.
Kruskal–Wallis test with a Dunn’s post hoc test and Mann–
Whitney U-test were used to analyse study participants’ clinical
characteristics. Friedman test with Dunn’s multiple comparison
test was used to compare matched ELISA data. For non-parametric
longitudinal data a Friedman repeated measures test was used to
determine signiﬁcance of changes over gestation in normP and PE.
Statistical analyses were carried out using Prism software. p < 0.05
was considered statistically signiﬁcant.
3. Results
Within the study groups, matching criteria did not differ. PE
groups had high proteinuria and signiﬁcantly higher blood
pressure (p < 0.002), lower birthweights (p < 0.05–p < 0.002)
and shorter gestations (p < 0.002) compared to the normP group
(Tables 1 and 2).
In both the early onset and late onset PE groups, plasma AFVDBP
levels were signiﬁcantly higher in normP compared to nonPr
(p < 0.01) (Fig. 1Ai). With established early onset PE, plasma
AFVDBP levels tended to be lower than normP but not signiﬁcantly.
In both early onset and late onset PE, plasma gelsolin levels were
signiﬁcantly lower than nonPr controls (p < 0.05). Although there
was a trend for gelsolin levels to be lower in normP than the nonPr
group, this was not statistically signiﬁcant (Fig. 1Aii). pre-eclamptic (PE) women recruited to a longitudinal study samples investigating
l pregnancy and prior to and following development of pre-eclampsia (PE). Plasma
n as median (range).
od pressure (mm Hg)
stolic) (diastolic)
Proteinuria (mg/24 h) Birthweight (g)
 N/A N/A
/76.5 (116–136) (70–91) None detected 3223 (2530–4000)
/110*** (126–180) (94–128) 2570.5 (586–14645) 2597* (1560–5788)
Fig. 1. (Ai) Plasma actin free vitamin D binding protein (AFVDBP) and (Aii) gelsolin levels in plasma samples from women with early onset (<33 weeks gestation) or late onset
(36 weeks gestation) PE, and matched normal pregnant (normP) and non-pregnant (nonPr) women (n = 10/group) and (Bi) AFVDBP and (Bii) gelsolin levels throughout
pregnancy in women who developed PE and matched normP (n = 10). Blood samples were taken in each trimester of pregnancy (1–3) and at the diagnosis of PE, and compared
to non-pregnant (nonPr) matched women. Bars represent median values. a: p < 0.001 and b: p < 0.01 when compared to nonPr.
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to nonPr (p < 0.001) during the ﬁrst trimester and increased
further as pregnancy advanced (p < 0.001). This was also seen in
pregnancies subsequently complicated with PE (p < 0.01) but the
later rise in AFVDBP was not apparent (Fig. 1Bi). Plasma gelsolin
levels fell signiﬁcantly during normal pregnancy (p = 0.0002),
with greater variability in pregnancies that subsequently devel-
oped PE (Fig. 1Bii). Third trimester gelsolin levels were signiﬁ-
cantly lower than nonPr levels in both the normP and PE groups
(p < 0.001) (Fig. 1Bii). Finally, plasma gelsolin levels were
signiﬁcantly lower in established PE compared to those measured
in the second trimester, prior to the onset of clinical symptoms
(Fig. 1Bii).
4. Comments
We have extended previous observations of raised VDBP during
normal pregnancy [20–22] and shown increased actin binding
capacity of VDBP during normal pregnancy. A ﬁrst trimester rise
was evident in both normal pregnancies and pregnancies that
subsequently developed PE. This is compatible with VDBP being an
acute phase reactant [23] and that normal pregnancy is associated
with an early and progressive low grade, systemic inﬂammatory
response, with increased circulating C-reactive protein in the ﬁrst
trimester [24]. AFVDBP levels, however, plateaued in pregnancieswhere PE later developed, suggesting more actin bound VDBP,
caused by increased extracellular actin levels. Alternatively, a
reduced placental contribution to circulating VDBP levels in PE
may account for the failure of AFVDBP to continue to rise during
the second and third trimesters [25]. This is also the ﬁrst report of
falling plasma gelsolin levels during normal and PE pregnancy.
Possible mechanisms behind this fall include increased turnover
due to clearance of actin complexed gelsolin or cleavage by matrix
metalloproteases whereupon gelsolin loses its actin binding
capacity [26,27]. The further decrease in gelsolin and AFVDBP in
established PE suggests that decreased gelsolin and AFVDBP is a
consequence of PE rather than a cause. A larger longitudinal study
is required, however, to determine the time course of the reduction
in circulating gelsolin in severe and mild forms of PE. Prophylactic
gelsolin/VDBP treatment to reduce the multi-organ damage seen
with the most severe forms of PE may still warrant further
investigation.
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